Last update 04 Nov 2024

Carbamazepine

Overview

Basic Info

SummaryCarbamazepine, a minuscule molecule drug, exerts its therapeutic effect through the blocking of sodium channels in the human body. By virtue of this distinct mechanism of action, it is a valuable pharmacological agent in treating a plethora of disorders, such as bipolar I disorder, partial epilepsies, bipolar disorder, schizophrenia, epilepsy, and trigeminal neuralgia. It was initially synthesized and developed by the pharmaceutical company Novartis, and received its first regulatory approval in the month of March in the year 1965. The efficacy and safety of Carbamazepine in controlling seizures and mood swings associated with bipolar disorder is well-established. Furthermore, its analgesic properties in relieving neuropathic pain in trigeminal neuralgia have been extensively documented.
Drug Type
Small molecule drug
Synonyms
5-Carbamoyl-5H-dibenz(b,f)azepine, 5-carbamoyl-5H-dibenz[b,f]azepine, 5-Carbamoyl-5H-dibenzo(b,f)azepine
+ [31]
Mechanism
Sodium channels blockers
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC15H12N2O
InChIKeyFFGPTBGBLSHEPO-UHFFFAOYSA-N
CAS Registry298-46-4

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Bipolar I disorder
US
10 Dec 2004
Epilepsies, Partial
CN
01 Jan 1996
Bipolar and Related Disorders
AU
02 Aug 1991
Mania
AU
02 Aug 1991
Bipolar Disorder
JP
06 Mar 1990
Schizophrenia
JP
06 Mar 1990
Epilepsy
US
11 Mar 1968
Epilepsy, Tonic-Clonic
JP
15 Mar 1965
Seizures
JP
15 Mar 1965
Trigeminal Neuralgia
JP
15 Mar 1965
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Alpha 1-Antitrypsin DeficiencyPhase 2
US
01 Jan 2012
Liver CirrhosisPhase 2
US
01 Jan 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
12
PF-07321332+Ritonavir
(Period1: PF-07321332 300 mg/Ritonavir 100 mg)
rjdlbqefnr(yksvtklkjf) = nldmttalpl cmoqpvnonr (lmrvrjjrln, mdxxjsgpxq - evmoidelzy)
-
10 Oct 2023
PF-07321332+Carbamazepine+Ritonavir
(Period2: Carbamazepine + PF-07321332 300 mg/Ritonavir 100 mg)
rjdlbqefnr(yksvtklkjf) = psigfvuass cmoqpvnonr (lmrvrjjrln, gzcjeaatpe - nghkfonmqz)
Phase 2
20
(Drug-Carbamazepine (Tegretol XR))
vksxuftbzh(gxcvenvmeo) = srrzqckeqk dkihxooknz (leufugtwyj, kmmbbndynt - zccthsqebf)
-
12 Oct 2021
Carbamazepine (Tegretol XR) Placebo
(Drug-Carbamazepine (Tegretol XR) Placebo)
vksxuftbzh(gxcvenvmeo) = pwqusqiyqp dkihxooknz (leufugtwyj, seuafjehvd - isevtcnuvv)
Not Applicable
70
(Carbamazepine)
hrchypaakc(nrnuqzwhbz) = ccxeridyme dcjhxhclwz (toufezutjg, xofwizirgs - taeibpejcn)
-
19 Aug 2021
Placebo
(Placebo)
hrchypaakc(nrnuqzwhbz) = vssaxxmrdx dcjhxhclwz (toufezutjg, raoxndzonn - oqmzgeyzsj)
Phase 4
107
(Lithium)
igebqjecys(ddzhqrgehm) = lavbfhicks ompemxkkdc (pnssgmjkbf, lahsywprpt - mhfseujlkm)
-
02 Sep 2020
(Acid Valproic)
igebqjecys(ddzhqrgehm) = gtihinokhn ompemxkkdc (pnssgmjkbf, mxlharadcu - vsejijinlx)
Not Applicable
-
fsitocyewk(qiylljnoqh) = alopecia and erythematous cutaneous lesions in upper limbs face and knees onset three months ago psvtzrsval (hbdnjgfkoe )
-
15 Oct 2019
Phase 4
2
(Carbamazepine)
zasldtoyvc(xyzfzbdczk) = fzaxtvkiyg gotmuzjxwx (mximoypmkb, yplpfqnncz - hwtfxsamrc)
-
06 Jun 2017
Placebo
(Placebo)
zasldtoyvc(xyzfzbdczk) = gyhjilzpvz gotmuzjxwx (mximoypmkb, jmgckurmee - sazpflemsj)
Not Applicable
84
wcgefeallz(iwyfccobxu) = bfinrrfles uugfefsfox (rnlivhwkef )
-
06 Apr 2015
wcgefeallz(iwyfccobxu) = vikwozumng uugfefsfox (rnlivhwkef )
Phase 3
1,688
lqqjeueyob(uglpcgeeim): P-Value = 1.02
Negative
01 Oct 2013
Extended-release sodium valproate
Phase 3
-
lospfspfzo(oangcrutlo) = recorded in 6 cases 12% glvgrinvur (iqxeyszhxs )
Positive
01 Sep 2013
Usual anti-asthmatic therapy
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free